Forte Biosciences, Inc.
FBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.03 | 0.03 | 0.02 |
| FCF Yield | -46.48% | -111.01% | -47.08% | -55.79% |
| EV / EBITDA | -1.24 | -0.43 | 1.71 | 0.57 |
| Quality | ||||
| ROIC | -69.74% | -91.99% | -35.80% | -51.71% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.91 | 0.59 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -6.90% | -251.79% | 50.92% | 9.48% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 0.37 | 2.97 | 1.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -45,662.44 | -57,751.11 | 0.00 | -9,591.39 |